Drugs used for the treatment of myocardial ischemia
Hardman JG et al. McGraw-Hill, New York
Robertson RM and Robertson D "Drugs used for the treatment of myocardial ischemia". In: Hardman JG et al. "Goodman and Gilman's The Pharmacological basis of therapeutic" 9th ed. McGraw-Hill, New York 1996: 759-779.
Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina
Detry JM et al. "Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina" Br J Clin Phannacol 19; 37: 279-288.
Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study
Dalla-Volta S et al. "Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study" Cardiovasc Dnys Tlter 19; 4: 853-860.
Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina
Michaelides AP et al. "Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina" Clin Drug Invest 19; 13 (1):8-14.
"Isosorbide dinitrate". In: "British National Formulary" British Medical Association and Royal Pharmaceutical Society of Great Britain, March 1999; (37): 95-96.
Évaluation de l'efficacité thérapeutique de Vastarel 20 mg (trimétazidine) au cours des syndromes cochléo-vestibulaires. Étude à double insu contre placebo
Wayoff M "Évaluation de l'efficacité thérapeutique de Vastarel" 20 mg (trimétazidine) au cours des syndromes cochléo-vestibulaires. Étude à double insu contre placebo" Ann Qto-Laryng 19; 101: 365-369.
Étude de l'efficacité de la trimé tazidine dans les désordres cochléovestibulaires d'origine ischémique. Essai en cross over contrôlé versus placebo
Coyas A "Étude de l'efficacité de la trimé tazidine dans les désordres cochléovestibulaires d'origine ischémique. Essai en cross over contrôlé versus placebo" Ann Oto-Larynj 19; 107: 82-87.